Drugging the efferocytosis process: concepts and opportunities

Nat Rev Drug Discov. 2022 Aug;21(8):601-620. doi: 10.1038/s41573-022-00470-y. Epub 2022 Jun 1.

Abstract

The daily removal of billions of apoptotic cells in the human body via the process of efferocytosis is essential for homeostasis. To allow for this continuous efferocytosis, rapid phenotypic changes occur in the phagocytes enabling them to engulf and digest the apoptotic cargo. In addition, efferocytosis is actively anti-inflammatory and promotes resolution. Owing to its ubiquitous nature and the sheer volume of cell turnover, efferocytosis is a point of vulnerability. Aberrations in efferocytosis are associated with numerous inflammatory pathologies, including atherosclerosis, cancer and infections. The recent exciting discoveries defining the molecular machinery involved in efferocytosis have opened many avenues for therapeutic intervention, with several agents now in clinical trials.

Publication types

  • Review

MeSH terms

  • Apoptosis*
  • Atherosclerosis* / drug therapy
  • Homeostasis
  • Humans
  • Phagocytes
  • Phagocytosis